Back to today’s briefing

Story perspectives

Medtronic Shares Slide Despite Strong Earnings and Guidance

2/19/2025

50 7

Summary

Story summary

Medtronic's shares dropped 7.3% after Q3 revenue of $8.29 billion fell short of the $8.33 billion estimate.
Surgical device sales declined due to changes in distributor buying patterns and increased competition.
Adjusted earnings per share reached $1.39, surpassing expectations.
The diabetes unit experienced an 8.4% sales increase, exceeding forecasts.
Medtronic upholds its full-year guidance for 4.75% to 5% organic sales growth.

History

Historical Context

Medtronic's recent revenue dip echoes the 2008 financial crisis, where healthcare firms faced similar distributor shifts and competition increases. Back then, regulatory changes and market dynamics reshaped the industry, leading to a more competitive landscape. Today's challenges reflect those historical shifts, driving Medtronic's strategic adjustments.

1 of 2

Story summary

Medtronic's shares dropped 7.3% after Q3 revenue of $8.29 billion fell short of the $8.33 billion estimate.
Surgical device sales declined due to changes in distributor buying patterns and increased competition.
Adjusted earnings per share reached $1.39, surpassing expectations.
The diabetes unit experienced an 8.4% sales increase, exceeding forecasts.
Medtronic upholds its full-year guidance for 4.75% to 5% organic sales growth.

1 / 2